Compare Nebius Group NV (NBIS) vs Sanofi SA (SNY) Price & Performance

Nebius Group NVTrade

Sanofi SATrade

Price performance (Past 24H)

Key statistics

Nebius Group NV vs Sanofi SA — how do they compare? Nebius Group NV trades at $219.22 (market cap $46.37B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 2.3× Nebius Group NV's market cap, and Sanofi SA pays a 5.5% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.

	NBIS	SNY
Market Cap	$46.37B	$104.83B
Sector	Technology	Health
52-Week High	$286.69	$52.34
52-Week Low	$50.40	$41.33
Enterprise Value	$46.56B	$121.32B
Dividend Yield	—	5.5%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NBIS

Nebius shares jump 13% after Nvidia reveals 9.3% stake, deepening AI partnership.Proactive Investors · 9 hours agoBullish Nvidia invests $2B in Nebius, Samsung launches Galaxy Card, Cracker Barrel beats revenue outlook.Seeking Alpha · 14 hours agoBullish Nebius shares jump as Nvidia reveals 9.3% stake in Dutch AI cloud companyCNBC · 15 hours agoBullish View details →

SNY

Sanofi reshapes Executive Committee to drive its next strategic phase starting September 2026GlobeNewsWire · 9 hours agoNeutral View details →

About Nebius Group NV

Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.